Mike Mussallem, the Chairman and CEO of Edwards Lifesciences

The China International Import Expo (CIIE) is an important event to showcase our leading medical technologies and therapies aimed at helping to improve outcomes for Chinese patients, Mike Mussallem, the Chairman and CEO of Edwards Lifesciences said in relation to the ongoing event.

"Our ongoing goal is to be a trusted partner that supports a healthier China, and we are excited to offer sophisticated and high-quality products that address the needs of Chinese patients," Mussallem said.

As the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring, Edwards Lifesciences has participated in CIIE for three consecutive years to introduce innovative products and explore local cooperation, accelerate local investment in China and benefit more Chinese patients.

With an area of 300 square meters, the booth is designed to convey the company's innovations and discoveries in the field of valve disease and hemodynamics to save patients' lives and improve their quality of life.

During the CIIE, Edwards will showcase its innovative products, cooperation with local companies, and patient outcomes, so as to advance in the journey of introducing innovative products and develop innovative cooperation.

Our "Patients First" approach means that we focus on developing and improving technologies that enable better outcomes for patients. Today, we know there are still big unmet needs among structural heart patients and the critically ill, Mussallem added.

Edwards continues to progress in the transcatheter aortic valve business and will release its two-year clinical data of the treatment of Chinese patients with SAPIEN 3 Transcatheter Aortic Valve System since its launch in China.

The SAPIEN 3 Aortic Valve System is the first and currently, the only balloon-expandable transcatheter aortic valve system approved for launch in China. It is widely used all over the world and is one of the most clinically evidenced transcatheter heart valves. Based on advanced technological innovation, this system enjoys a high procedure success rate.

Since its debut at the 2020 CIIE, the SAPIEN 3 valve has successfully landed in more than 70 implantation facilities in 23 provinces and cities across China. Edwards surgical heart valve portfolio continues to gain momentum, bringing collective appearance of series products equipped with RESILIA tissue.

In addition, Edwards will bring the next generation of RESILIA tissue series, the MITRIS RESILIA mitral bioprosthesis valve.

Based on the Carpentier-Edwards PERIMOUNT platform, which has been on the market for more than 40 years, the product has been approved for launch in the US, Japan, and Canada. It will take advantage of CIIE to achieve its Chinese debut and is planned to be introduced as an approved technology to the Chinese market.

During 2021's CIIE, Edwards and Mindray Medical entered a strategic partnership to develop an innovative interface solution, and integrate Edwards FloTrac series products into Mindray's BeneVision N series medical monitors.

Benefiting from the accelerating effect of CIIE, this product has been successfully launched in Chinese market in June this year and has officially landed in major hospitals in Beijing and Hebei, successfully helping dozens of clinical patients, which practices the determination of both parties to bring quality medical care to the vast markets of lower-tier cities in China, and serve more Chinese patients..

In August 2022, Edwards HemoSphere advanced a monitoring platform equipped with Hypotension Prediction Index Software, which had successfully launched in China. It becomes another example of benefiting from the "exhibits to commodities" pathway facilitated by the CIIE. The above two signature products will also be unveiled at Edwards booth at this CIIE. In addition, Edwards new consumable product, ForeSight tissue oximetry system, will also be exhibited for the first time.

Edwards set up one new legal entity in Hong Kong this July, which will further accelerate the introduction of more innovative products into Chinese mainland.